Drug Insight: abatacept for the treatment of rheumatoid arthritis (Q36667805)

15 August 2017

1 reference

title

Drug Insight: abatacept for the treatment of rheumatoid arthritis (English)

1 reference

15 August 2017

1 reference

Eric M Ruderman

1

0 references

Richard M. Pope

object named as

Richard M Pope

series ordinal

2

0 references

publication date

1 December 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

654-660

1 reference

Evolving concepts of rheumatoid arthritis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Abandoned therapies and unpublished trials in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

CTLA4Ig: bridging the basic immunology with clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

B7/CD28 costimulation is essential for the homeostasis of the CD4 CD25 immunoregulatory T cells that control autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

CTLA-4 ligation blocks CD28-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

CTLA-4: a negative regulator of autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Regulatory T-cell therapy: is it ready for the clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

How do CD4 CD25 regulatory T cells control autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4 CD25 Regulatory T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

inferred from DOI database lookup

7 January 2021

based on heuristic

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0345

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NCPRHEUM0345

1 reference

Dimensions Publication ID

15 August 2017

1045846307

0 references

1 reference